Gastroenterology Abstracts On The Go

University of Connecticut
  • 5.0 (1)
  • MEDICINE
  • UPDATED WEEKLY

A monthly deep dive into the most influential and practice-shaping publications in Gastroenterology. Each episode breaks down key studies, highlights clinical implications, and offers clear, evidence-based insights for busy clinicians, trainees, and researchers. Whether it’s landmark trials, emerging therapies, or updated guidelines, this podcast brings the latest GI literature to life—helping listeners stay current, think critically, and apply new knowledge at the bedside.

  1. FEB 12

    JAMA February 2026 Prevalence of Colorectal Cancer Screening Among Latino Adults Following the Medicaid Eligibility Amendment Expansion

    This research study investigates whether broadening Medicaid eligibilityto include low-income adults regardless of their immigration status helps improve preventative healthcare outcomes. By comparing patients in states that adopted these inclusive policies against those that did not, the authors found a significant increase in colorectal cancer screenings among various Latino and Latina subgroups. These findings highlight that eliminating insurance barriers is a vital strategy for addressing health disparities, as cancer remains a primary cause of mortality within these communities. Ultimately, the text suggests that state-funded coverage expansions serve as an effective tool for boosting life-saving medical checkups among historically underserved populations.

    14 min

  2. FEB 10

    BMJ Gut February 2026:Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma

    This research investigates why most liver cancer patients fail to respond to standard combined immunotherapy, identifying a protein called galectin-4as a primary culprit behind treatment resistance. By stabilizing metabolic enzymes and triggering specific chemical signals, galectin-4 forces the tumor into a state of metabolic adaptation that effectively shields it from the immune system. This process creates a hostile environment that neutralizes protective T cells while attracting suppressive cells that prevent the therapy from working. Ultimately, the study suggests that measuring galectin-4 levels can predict patient outcomes, and blocking this protein may provide a vital strategy for restoring the effectiveness of life-saving cancer treatments.

    15 min

  3. FEB 10

    BMJ GUT February 2026:Towards optimising and standardising donor screening for faecal microbiota transplantion.

    To address the lack of uniform evidence-based standards, this article proposes a rationalized framework for screening stool donors to ensure the safety of fecal microbiota transplants. The authors conducted a comparative review of existing guidelines and utilized an expert Delphi process to balance the prevention of pathogen transmission with the need to maintain an adequate donor supply. By advocating for increased transparency and rigorous record-keeping, the text emphasizes a structured approach to tracking donor health and procedural outcomes. Ultimately, the research aims to modernize clinical practices by integrating emerging metagenomic technologies to better identify potential risks and streamline the donor selection process.

    14 min

  4. FEB 5

    Lancet Gastroenterology Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.Background

    The SHINE-1 study explored the potential of mirikizumab, a specialized antibody treatment, for children and adolescents suffering from moderate-to-severe ulcerative colitis who had failed previous therapies. By blocking a specific inflammatory protein known as IL-23, the drug aimed to reduce intestinal damage and provide long-term relief through a sequence of intravenous and subcutaneous doses. The findings revealed that a significant portion of young patients achieved clinical and endoscopic remission by the end of the year-long trial, often without the need for steroids or surgery. While some participants experienced mild side effects like headaches or injection site pain, the overall safety and efficacy results suggest that this treatment is a promising alternative for pediatric patients facing difficult-to-manage bowel disease.

    16 min

  5. JAN 28

    JAMA Gastroenterology January 2026:Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial

    This long-term clinical study evaluates whether treating uncomplicated appendicitis with medication is a viable alternative to traditional surgery over a ten-year period. By tracking hundreds of patients, researchers found that while nearly 40% of those who took antibiotics eventually experienced a recurrence, the majority avoided surgery entirely without sacrificing their overall quality of life. Notably, the group treated with antibiotics suffered significantly fewer medical complications than those who underwent an appendectomy. These findings suggest that for many adults, a non-surgical approach is a safe and effective primary option for managing this common condition.

    17 min

  6. JAN 28

    Gastroenterology February 2026: The Prevalence and Burden of Avoidant/Restrictive Food Intake Disorder Symptoms in Adults With Disorders of Gut-Brain Interaction: A Population-Based Study

    This population-based study investigates the strong correlation between disorders of gut-brain interaction (DGBI) and avoidant/restrictive food intake disorder (ARFID) among the general adult population in the United Kingdom and United States. The researchers discovered that individuals suffering from digestive issues are significantly more likely to restrict their food intake, with the risk of disordered eating rising as the anatomic regions affected by gut issues increase. Beyond simple dietary avoidance, the presence of both conditions leads to a higher overall health burden, including psychological distress, lower quality of life, and increased medical costs. Ultimately, the text advocates for integrated clinical screening to ensure that patients receive comprehensive care from a combined team of medical and mental health professionals.

    15 min

  7. JAN 28

    Gastroenterology February 2026:The Disease Burden of Helicobacter pylori Beyond Gastric Cancer

    While health policies often focus on the link between Helicobacter pylori and stomach cancer, this research highlights the massive global burden of other conditions caused by the bacteria, such as peptic ulcers and indigestion. By analyzing international data, the authors demonstrate that eradicating the infection could prevent millions of cases of illness, suggesting that current medical guidelines significantly underestimate the total clinical advantagesof mass screening. The study concludes that future health assessments must include these secondary benefits to accurately reflect the true value and cost-effectiveness of widespread treatment programs.

    13 min

  8. JAN 18

    Clinical Gastroenterology and Hepatology; January 2026 Long-Term Mortality After Cholecystectomy in a Nationwide Cohort of Swedish Individuals Between 1969 and 2016

    This nationwide Swedish study investigated the long-term survival rates of nearly 160,000 patients who underwent gallbladder removal surgery over several decades. By comparing these patients to the general public, researchers discovered a distinct age-based disparity in mortality outcomes following the procedure. While older patients generally experienced lower mortality, those who had the surgery between the ages of 20 and 39 faced a higher risk of death, often linked to lifestyle factors like smoking and alcohol consumption. Ultimately, the research suggests that while cholecystectomy is generally safe, the underlying health and habitsof younger patients may play a critical role in their long-term recovery and lifespan.

    18 min
See All (41)

About

A monthly deep dive into the most influential and practice-shaping publications in Gastroenterology. Each episode breaks down key studies, highlights clinical implications, and offers clear, evidence-based insights for busy clinicians, trainees, and researchers. Whether it’s landmark trials, emerging therapies, or updated guidelines, this podcast brings the latest GI literature to life—helping listeners stay current, think critically, and apply new knowledge at the bedside.

Information